NCT05512351View on ClinicalTrials.gov

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 23, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2026

Conditions
Oligodendroglioma
Interventions
DRUG

Tislelizumab plus Bevacizumab

200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks.

Trial Locations (1)

450003

RECRUITING

Henan Provincial People's Hospital, Zhengzhou

All Listed Sponsors
lead

Henan Provincial People's Hospital

OTHER